top of page
Search

How Placental Stem Cells Are Shaping New Approaches to Lung Disease

  • DPS
  • 8 hours ago
  • 2 min read

Emerging research highlights the potential of placental mesenchymal stem cells (P-MSCs) in addressing various lung conditions. These cells, derived from the placenta, possess unique properties that may offer therapeutic benefits for respiratory ailments.


Potential Applications in Lung Disorders

1. Acute Respiratory Distress Syndrome (ARDS)

A phase I clinical trial investigated the safety of intravenous administration of placenta-derived mesenchymal stem cells in patients with COVID-19-induced ARDS. The study found that the treatment was safe and well-tolerated, with no adverse events reported. While the primary focus was on safety, the findings support further research into the efficacy of P-MSCs in ARDS treatment.


2. Pulmonary Fibrosis

Preclinical studies have demonstrated that stem cells from the placental amniotic membrane can slow the progression of scarring in pulmonary fibrosis. In mouse models, these cells reduced lung fibrosis, potentially by creating a microenvironment that limits chronic inflammation leading to scarring.


3. Bronchopulmonary Dysplasia (BPD) in Premature Infants

Clinical trials in Australia are exploring the use of placental stem cells to treat premature babies suffering from chronic lung disease, specifically BPD. The aim is to combat the effects of this condition and improve respiratory outcomes in these vulnerable patients.



Illustration depicting how stem cells from the placental amniotic membrane can slow lung scarring in pulmonary fibrosis.
Image source: World Stem Cell Summit.  Image used under fair use for educational and informational purposes.


Conclusion

Placental stem cells offer a promising avenue for the treatment of various lung disorders. While early studies and clinical trials indicate safety and potential efficacy, further research is essential to fully understand their therapeutic capabilities and to establish standardized treatment protocols.


Sources

  1. Aghayan HR, et al. Stem Cell Research & Therapy (2022)."Human placenta-derived mesenchymal stem cells transplantation in patients with ARDS caused by COVID-19."

  2. World Stem Cell Summit (2020)."Stem cells from placental amniotic membrane slow lung scarring in pulmonary fibrosis."

  3. Cells4Life (2018)."Placenta stem cells treating lung disease."

 
 
 

Comments

bottom of page